Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company's lead ddCAR product candidate is CART-ddBCMA, which is in phase 1 clinical trial for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM). It is also developing ACLX-001, an immunotherapeutic combination composed of ARC-T cells and bi-valent SparX proteins targeting BCMA to treat r/r MM; ACLX-002 and ACLX-003 for treating r/r acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS); and other AML/MDS product candidates, as well as solid tumor programs. The company was formerly known as Encarta Therapeutics, Inc. and changed its name to Arcellx, Inc. in January 2016. Arcellx, Inc. was incorporated in 2014 and is headquartered in Gaithersburg, Maryland.

Arcellx, Inc.

We are a clinical-stage biotechnology company reimagining cell therapy through the development of innovative immunotherapies.


Kite Pharma

JVC Investment Partners

LG Technology Ventures

Solasta Ventures

Samsara BioCapital

Novo Holdings

Adage Capital Management

Asymmetry Ventures

CaaS Capital Management

Cambrian Biopharma

CAM Capital

Clough Capital Partners

Soleus Capital

SR One

Surveyor Capital

Suvretta Capital Management

Takeda Ventures

Terra Magnum Capital Partners (""""TMCP"""")""

Arcellx

	Dec '19	Dec '20	Dec '21	Dec '22	Dec '23
revenue					110.32M -
cost of revenue					2.04M -
gross profit					108.28M -
selling and marketing expenses					-2.04M -
general and administrative expenses	2.21M -	7.04M 218.84%	18.14M 157.60%	41.70M 129.96%	66.35M 59.10%
selling general and administrative expenses	2.21M -	7.04M 218.84%	18.14M 157.60%	41.70M 129.96%	64.31M 54.21%
research and development expenses	15.77M -	25.06M 58.92%	46.88M 87.11%	149.56M 219.00%	133.85M 10.50%
other expenses	2K -	1K 50%	49K 4,800%
cost and expenses	17.97M -	32.10M 78.57%	65.02M 102.57%	191.26M 194.16%	200.20M 4.67%
operating expenses	17.97M -	32.10M 78.57%	65.02M 102.57%	191.26M 194.16%	198.16M 3.61%
interest expense				1.72M -	3.84M 123.37%
ebitda	-17.65M -	-31.47M 78.30%	-65.02M 106.62%	-186.96M 187.55%	-87.84M 53.02%
operating income	-17.97M -	-32.10M 78.57%	-65.02M 102.57%	-191.26M 194.16%	-89.88M 53.01%
depreciation and amortization	326K -	629K 92.94%	1.04M 65.50%	4.30M 313.06%	2.04M 52.56%
total other income expenses net	2K -	1K 50%	49K 4,800%	2.58M 5,165.31%	19.85M 669.50%
income before tax	-17.97M -	-32.09M 78.58%	-64.97M 102.43%	-188.68M 190.41%	-70.03M 62.89%
income tax expense			-1.04M -	-2.58M 147.84%	663K 125.70%
net income	-17.97M -	-32.09M 78.58%	-63.93M 99.18%	-186.10M 191.11%	-70.69M 62.01%
weighted average shs out	10.78M -	21.78M 101.94%	33.54M 54.04%	36.36M 8.38%	48.06M 32.20%
weighted average shs out dil	10.78M -	21.78M 101.94%	33.54M 54.04%	36.36M 8.38%	48.06M 32.20%
eps	-1.67 -	-1.47 11.98%	-1.91 29.93%	-5.12 168.06%	-1.47 71.29%
epsdiluted	-1.67 -	-1.47 11.98%	-1.91 29.93%	-5.12 168.06%	-1.47 71.29%

COM:ARCELLX

Arcellx, Inc.

Last Close

87.22

22/11 21:00

Market Cap

3.07B

Beta: -

Volume Today

342.91K

Avg: -

Preview